An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening
Guardant Health (Nasdaq: GH) announced a temporary halt in trading of its stock on Nasdaq. This pause precedes a important meeting of the FDA's Molecular and Clinical Genetics Panel, which will review the premarket approval application for Shield™, Guardant Health’s blood test aimed at screening colorectal cancer in average-risk adults. The panel meeting, starting at 9:30 a.m. ET, will provide independent expert advice to the FDA to support its decision-making process.
Positive
FDA panel review could lead to ShieldTM blood test approval, potentially opening a new revenue stream.
Positive panel outcome may enhance company reputation and investor confidence.
Negative
Temporary halt in stock trading may cause uncertainty and volatility among investors.
Dependence on FDA panel's non-binding recommendation adds an element of risk.
Guardant Health's trading halt by Nasdaq indicates a significant event, as trading halts are typically reserved for important and potentially market-moving announcements. The FDA panel's review of the PMA application for the Shield blood test is a critical moment for the company. If approved, Shield could become a groundbreaking product in colorectal cancer screening. Guardant Health's stock may see volatility based on the outcome, with potential positive movement if the FDA panel gives a favorable recommendation. Investors should watch for the panel's decision and subsequent FDA actions, as these will directly impact Guardant Health's financial prospects and market valuation.
The Shield blood test aims to provide a non-invasive method for colorectal cancer screening, which could significantly improve early detection rates and patient compliance compared to traditional colonoscopies. If the test proves to be accurate and reliable, it could revolutionize colorectal cancer screening protocols. However, the FDA panel's evaluation will scrutinize the clinical data supporting the test's efficacy and safety. A positive assessment could lead to widespread adoption in the medical community, but any concerns raised could delay approval and impact the test’s market potential.
From a market perspective, the approval of the Shield blood test could position Guardant Health as a leader in the cancer diagnostics market, potentially capturing a significant share of the colorectal cancer screening segment. This market is currently dominated by traditional methods like colonoscopies and fecal tests. The convenience and non-invasiveness of a blood test could drive higher adoption rates, especially among individuals reluctant to undergo more invasive procedures. The FDA panel’s decision could shift market dynamics and influence competitor strategies, making it a pivotal moment for the industry.
PALO ALTO, Calif.--(BUSINESS WIRE)--
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Nasdaq has temporarily halted trading of the company's stock.
The Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration (FDA) Medical Devices Advisory Committee will meet today to review the premarket approval (PMA) application for ShieldTM, Guardant Health’s blood test to screen for colorectal cancer in average-risk adults.
The panel meeting is scheduled to begin at 9:30 a.m. ET.
FDA advisory committees provide independent expert advice and non-binding recommendations to the FDA on certain products to help the agency make sound decisions based on the available science.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
